

Chinawa JM

# Adverse Drug Event From Artemether/lumefantrine Ingestion: Case Series

DOI:<http://dx.doi.org/10.4314/njp.v40i4.13>

Accepted: 4th March 2013

Chinawa JM (✉)

Department of Paediatrics

University of Nigeria, Enugu Campus,

&amp; University of Nigeria Teaching Hospital, Ituku - Ozalla, Enugu.

Email: josephat.chinawa@unn.edu.ng

**Abstract** We present rare cases of three adverse drug events from artemether-Lumefantrine (AL) ingestion. This is an antimalaria combination therapy used in the management of malaria. Adverse reaction is rarely reported when using this drug.

We report these cases of our patients who developed urticaria and bullae. One had hypotension few hours after taking AL. We report

these cases to show that though rare, adverse drug event can occur in AL.

**Conclusion:** Artemisinin combination therapy though safe in children, is not without adverse reaction.

**Key Words:** artemether-Lumefantrine; Children; Adverse drug event.

## Introduction

Malaria is one of the most significant causes of morbidity and mortality worldwide, causing approximately 881,000 deaths every year.<sup>1</sup> The current WHO guidelines for the treatment of malaria recommend the use of artemisinin-based combination therapy (ACT) owing to *Plasmodium falciparum* resistance to monotherapy.<sup>2</sup> Artemether/lumefantrine (AL) was the first fixed-dose combination of ACT to be approved by the European regulatory authorities according to the requirements of the International Committee on Harmonization (ICH). Artemether is derived from the Chinese herb sweet wormwood (*Artemisia annua*). The antimalarial properties of artemether stem from interference with parasite transport proteins, disruption of parasite mitochondrial function, inhibition of angiogenesis, and modulation of host immune function.<sup>3</sup> Artemether is absorbed very rapidly after oral administration reaching peak plasma concentrations within 2 hours after dose.<sup>4,5</sup> It has a half-life of 1–3 hours. It is metabolized quickly via CYP450 2B6, CYP450 3A4 and possibly CYP450 2A6 to the more potent antimalarial metabolite DHA, which in turn is converted to inactive metabolites primarily by glucuronidation via UGT1A1, 1A8/9 and 2B7.<sup>6</sup> Artemether induces CYP450 2C19 and 3A4. These metabolites may be a major trigger for adverse reaction.

Lumefantrine is an aryl-amino alcohol that prevents detoxification of haem, such that toxic haem and free radicals induce parasite death.<sup>7</sup> Lumefantrine absorption occurs 2 hours after oral intake reaching peak plasma concentration after 3–4 hours.<sup>7</sup> It has a half life of 3–6 days and is responsible for preventing recurrent malaria parasitemia. Lumefantrine is metabolized by N-debutylation mainly by CYP450 3A4 to desbutyl-

lumefantrine with 5–8-fold higher antiparasitic effect than lumefantrine. Lumefantrine inhibits CYP450 2D6.<sup>8</sup>

Adverse effects are rare.<sup>3</sup> There have been case reports of neurological problems (including ataxia, nystagmus, tremor and slurred speech) occurring after administration of herbal artemisinin or artesunate monotherapy.<sup>9</sup> However, it is questionable whether these neurological effects are related to artemisinin treatment.

## Case series

### Case 1

YI is a 7 year old female who presented with fever and cough of 2 days duration. Fever was low grade and intermittent while cough was unproductive with no difficulty in breathing. An empirical diagnosis of Malaria was made, following this, mother gave TM (*Ajanta pharma limited. MFD 07/2011. EXP 06/2013*) 2 tablets (*40mg lumafanthrine+240mg artesunate*), twice a day for 3 days (*This is appropriate for child's weight*). Few hours after the first dose of the drug, she was found to have developed urticarial rashes on the face and bullae on the lips. This rash was itchy and makes patient uncomfortable. There was slight wheeze and catarrh. Child had been treated with this drug before. There was no history of drug allergy.

Examination revealed pyrexia (38°C), fast and rapid pulse (114 beats per minutes) and Blood pressure of 80/50mmHg. A diagnosis of adverse drug reaction was made. The drug was withdrawn and she was commenced on Intravenous promethazine and hydrocortisone for 3 days. The rash cleared, fever subsided and clinical signs were stable three days after therapy.

### Case 2

EK is a 3- year old male who presented in a clinic with a two days history of fever, vomiting, diarrhea and weakness of 3 days duration. On examination, he was found to be lethargic but in no obvious respiratory distress. Other findings were normal. He was diagnosed as acute uncomplicated malaria and then placed on Intravenous fluids and Intravenous Artesunate. Just few minutes later, we noted generalized urticarial rash and maculopapular rash. Vital signs were within normal ranges. A diagnosis of adverse drug reaction was made, and patient was placed on Intravenous hydrocortisone and promethazine. The rash cleared thereafter.

### Case 3

B is a 3 month old male who presented with fever and poor sucks at breast of three days duration. Systemic examination revealed no obvious abnormality. A tentative diagnosis of malaria was made. He was given intramuscular Artemether, after which fever subsided. The parenteral drug was then changed to syrup P-alaxin 8mls daily for three days. On the third day of commencement of this drug, baby was brought back to the hospital with an urticarial and maculopapular rash. Pulse rate then was 142 beat per minute and respiratory rate was 68 cycles per minute (tachypnoea). The patient was managed with antihistamine and low dose steroid; he is doing well as at the time of writing this report

## Discussion

Adverse drug reaction is an unpleasant reaction, which results from an intervention related to the use of a medicinal product which predicts hazard from future administration, and warrants prevention or a specific treatment or alteration of the dosage regimen or withdrawal of product.<sup>9</sup>

Adverse drug reactions caused by immune and nonimmune mechanisms are a major cause of morbidity and mortality worldwide. They are the most common iatrogenic illness, complicating 5 to 15 percent of therapeutic drug courses.<sup>10</sup> Three to six percent of all hospital admissions are because of adverse drug reactions, and 6 to 15 percent of hospitalized patients (2.2 million persons in the United States in 1994) experience a serious adverse drug reaction.<sup>10</sup>

The body's response can affect many organ systems but the skin is the organ most frequently involved as seen in

our patients.<sup>11</sup> Symptoms of Artemether -Lumefantrine vary and could present as urticarial rash, itching, swelling of the lips, wheezing, hives and systemic features as hypotension, fainting, palpitations etc. Our patients presented with urticarial rash, itching and swelling of the lips and hives but only one presented with hypotension.<sup>12</sup> At times it can make the skin blister and peel: A phenomenon called Toxic epidermal necrolysis (TEN).<sup>11</sup> None of our series presented with palpitations nor TEN. Combisunate is an artemether-lumefantrine derivative which side effects were mild, did not lead to artemether-lumefantrine discontinuation, and can resolve. Hartz et al noted that artemether-lumefantrine 6-dose regimen was discontinued in 0.2% of adult patients due to side effects. He also noted few adverse effects in his series.<sup>12</sup> Urticaria was reported in less than 3% of his patients. Serious skin reactions (bullous eruption) have been reported rarely during postmarketing experience.<sup>13</sup> Neurological deficits and ototoxicity have been reported in some cases of artemether -Lumefantrine ingestion.<sup>13</sup> Our series had urticaria and a bullous eruption on their lips but no neurological deficits or hearing problems. The relationship between the drug intake and the onset of clinical symptoms is critical. Unless the patient has been previously sensitized to a drug, the interval between initiation of therapy and the onset of reaction is rarely less than one week or more than one month.<sup>11</sup> Our first and second cases occurred few hours after initiation of therapy while the third occurred after two days.

The most important measure in managing drug hypersensitivity reactions is the discontinuation of the offending medication.<sup>14</sup> Alternative medications with unrelated chemical structures should be substituted when available. In the majority of patients, symptoms will resolve within two weeks if the diagnosis of drug hypersensitivity is correct.<sup>14</sup> All the signs and symptoms resolved in one of our patients within minutes while the other two happened in just three days after treatment. Additional therapy for drug hypersensitivity reactions is largely supportive and symptomatic.<sup>11</sup> Systemic corticosteroids may speed recovery (as in our patient) in some cases of drug hypersensitivity.<sup>11</sup> Topical corticosteroids and oral antihistamines may improve dermatologic symptoms. Antihistamines were used in all our cases and we had good response.

## Conclusion

Artemether-lumefantrine combination can lead to minor skin related adverse events.

## References

1. WHO World Malaria Report 2008. [Obtainable at <http://www.who.int/malaria/wmr2008/> accessed on May 2012]
2. WHO Guidelines for the treatment of malaria 2006 [obtainable at <http://www.who.int/malaria/docs/TreatmentGuidelines2006.pdf> accessed on May 2012]
3. Golenser J, Waknine JH, Krugliak M, Hunt NH, Grau GE. Current perspectives on the mechanism of action of artemisinins. *International Journal for Parasitology* 2006; 36: 1427-41.

3. White NJ, Van Vugt M, Ezzet F. Clinical pharmacokinetics and pharmacodynamics of artemether-lumefantrine. *Clinical Pharmacokinetics* 1999; 37: 105–25
5. Ezzet F, Van Vugt M, Nosten F, Looareesuwan S, White NJ. Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria. *Antimicrobial Agents and Chemotherapy* 2000; 44: 697–704
6. Aweeka FT, German PI. “Clinical pharmacology of artemisinin-based combination therapies. *Clinical Pharmacokinetics* 2008 ; 47: 91–102
7. Khoo S, Back D, Winstanley P. “The potential for interactions between antimalarial and antiretroviral drugs,” . *AID* 2005; 19: 995–1005
8. G. Kokwaro, L. Mwai, and A. Nzila, “Artemether/lumefantrine in the treatment of uncomplicated falciparum malaria. *Expert Opinion on Pharmacotherapy* 2007; 8: 75–94
9. Lancet IR, Aronson JK. Adverse drug reactions: Definitions, diagnosis, and management. *Lancet* 2000; 356:1255–9
10. Ditto AM. Drug allergy. In: Grammer LC, Greenberger PA, eds. *Patterson's Allergic diseases*. 6th ed. Philadelphia: Lippincott Williams & Wilkins, 2002:295.
11. Marc AR, Adrian MC. Adverse Drug Reactions: Types and Treatment Options. *Am Fam Physician* 2003; 68:1781–91.
12. Hatz C, Soto J, Nothdurft HD, Zoller T, Weitzel T, Loutan L, Bricaire F et al. Treatment of acute uncomplicated falciparum malaria with artemether-lumefantrine in nonimmune populations: a safety, efficacy, and pharmacokinetic study. *Am J Trop Med and Hyg* 2008; 78:241–7
13. Gürkov R, Eshetu T, Miranda IB, Berens-Riha N, Mamo Y, Girma T, Ototoxicity of artemether/lumefantrine in the treatment of falciparum malaria: a randomized trial. *Malar J* 2008, 7:17
14. Anderson JA, Adkinson NF Jr Allergic reactions to drugs and biologic agents *JAMA* 1987 ;258:2891–9.